UC San Diego researchers report that conducting genomic evaluations of advanced malignancies can be effective in guiding first-line-of-treatment, rather than waiting until standard-of-care therapies have failed.
Related Articles

News
Expert on U.S.-Mexico Relations Rafael Fernández de Castro Named to New Endowed Chair
April 1, 2022
sandiegobiotech
News, UCSD News
Comments Off on Expert on U.S.-Mexico Relations Rafael Fernández de Castro Named to New Endowed Chair
U.S.-Mexico relations expert Rafael Fernández de Castro has been named as the inaugural Aaron Feldman Family Chancellor’s Endowed Chair in U.S.-Mexican Studies in Memory of David Feldman.
[…]

News
Heart to Heart: Seven Couples Share Their UC San Diego Love Stories
February 10, 2022
sandiegobiotech
News, UCSD News
Comments Off on Heart to Heart: Seven Couples Share Their UC San Diego Love Stories
As Valentine’s Day approaches, we are celebrating all the lasting love stories that got their start right here at UC San Diego. To honor the day dedicated to love, we asked the Triton community to share their ma… […]

News
New Study Evaluates Hand-Held Device for Non-Surgical Therapy of Kidney Stones
October 14, 2019
sandiegobiotech
News
Comments Off on New Study Evaluates Hand-Held Device for Non-Surgical Therapy of Kidney Stones